Community Practice Connections™: ASCO Direct Highlights: Practice-Changing Data From The Leading Oncology Conference

Release Date: August 31, 2021
Expiration Date: August 31, 2022

Activity Overview

Fundamental changes to the management of cancer have led to substantial improvements for patients across the continuum of care for nearly every malignancy. The annual meeting of the American Society of Clinical Oncology is a premier venue for disseminating practice-changing clinical trial results that drive the evolution of treatment.

This Community Practice Connection™ program provides a review of some of the key highlights from the meeting series “ASCO Direct Highlights: Practice-Changing Data From The Leading Oncology Conference,” held through July 2021. This unique and engaging multimedia activity is ideal of community-based clinicians and focuses on the key updates from the annual oncology meeting across various malignancies. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Karyopharm Therapeutics and Sanofi Genzyme.

Target Audience

This educational activity is directed toward medical oncologists, as well as surgical oncologists, nurses, and pathologists. Nurse practitioners, physician assistants, pharmacists, researchers, and other health care professionals may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe strategies used for prognostic and predictive biomarker testing to assist in optimal clinical decision-making for patients with cancer
• Discuss recent clinical trial findings that have the potential to change clinical practices and optimize outcomes for patients with cancer
• Incorporate strategies for monitoring and mitigating adverse events associated with novel treatments into the clinical care of patients with cancer
• Explain recent trial evidence in the context of evolving treatment paradigms for cancer management

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Edward S. Kim, MD
Physician-in-Chief
City of Hope Orange County
Vice Physician-in-Chief
City of Hope National Medical Center
Los Angeles, CA

Disclosures: Consultant: A2, Roche/Genentech, BI.

Yelena Y. Janjigian, MD
Associate Professor
Chief, Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Bayer, Bristol Myers Squibb, Cycle for Sur-vival, Department of Defense, Eli Lilly and Company, Fred’s Team, Genentech/Roche, Merck, National Cancer Institute, RGENIX; Consultant: AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Imugene, Merck, Merck Serono, Pfizer, RGENIX, Seattle Genetics, Zymeworks.

Oliver Sartor, MD
C.E. & Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, LA

Disclosures: Grant Research Support: Advanced Accelerator Applications (Novartis), AstraZeneca; Bayer AG; Constellation Pharmaceuticals, Inc.; Endocyte (Novartis); Invitae Corporation; Janssen Pharmaceuticals; Merck; Progenics Pharmaceuticals, Inc.; Consultant: Advanced Accelerator Applications (Novartis), Astellas Pharma Inc.; AstraZeneca; Bayer AG; Bellicum Pharmaceuticals, Inc.; Blue Earth Diagnostics, Inc.; Bristol Myers Squibb; Clarity Pharmaceuticals; Constellation Pharmaceuticals, Inc.; Dendreon Pharmaceuticals; EMD Serono; POINT Biopharma/ITM Isotopen Technologien München AG; Janssen Pharmaceuticals; Merck, Myovant Sciences; Myriad Genetics; Noria Therapeutics, Inc.; Novartis; Noxopharm; Pfizer; Sanofi SA; Shareholder: GlaxoSmithKline, Johnson & Johnson, Lilly.

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
Dallas, TX

Disclosures: Consultant: AstraZeneca, Celgene Corporation, Eli Lilly and Company, Merck, Novartis, Pfizer, Seattle Genetics.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.